Royalty Pharma plc filed its quarterly report on Form 10-Q with the SEC for the three and nine months ended September 30, 2026, disclosing condensed consolidated financial statements and related disclosures as of that period.

Key Highlights

  • Share count: As of October 30, 2026, Royalty Pharma plc had 445,265,805 Class A ordinary shares outstanding and 128,339,498 Class B ordinary shares outstanding.
  • Total revenues, Q3 2026: Total income and other revenues were $690,103 thousand for the three months ended September 30, 2026, compared with $609,291 thousand for the same period in 2025.
  • Nine-month revenues: Total income and other revenues for the nine months ended September 30, 2026 were $1,994,820 thousand, versus $1,756,203 thousand for the nine months ended September 30, 2025.
  • Income from financial royalty assets: This line item was $647,608 thousand for Q3 2026 and $1,880,627 thousand for the nine months ended September 30, 2026.
  • Total assets: As of September 30, 2026, total assets were $19,461,223 thousand, compared with $19,620,780 thousand as of December 31, 2025.
  • Long-term debt: Long-term debt stood at $7,590,522 thousand as of September 30, 2026, down from $8,570,917 thousand as of December 31, 2025.

Royalty Pharma's Financial Position and Revenue for the Quarter Ended September 30, 2026

Royalty Pharma plc (NASDAQ:RPRX), incorporated in England and Wales and headquartered in New York, New York, operates as a buyer of biopharmaceutical royalties. The company acquires royalty interests in approved and development-stage products, and its primary source of income is cash flows from those financial royalty assets. The 10-Q for the quarterly period ended September 30, 2026 was filed for the period covered by the condensed consolidated financial statements included therein.

According to the filing, total income and other revenues for the three months ended September 30, 2026 were $690,103 thousand, with income from financial royalty assets contributing $647,608 thousand and other royalty income and revenues adding $42,495 thousand. For the comparable three-month period in 2025, the filing reported total income and other revenues of $609,291 thousand. The nine-month figures showed total income and other revenues of $1,994,820 thousand for 2026 versus $1,756,203 thousand for 2025, according to the condensed consolidated statements of operations.

The condensed consolidated balance sheet as of September 30, 2026 showed total assets of $19,461,223 thousand, with financial royalty assets, net, of $16,141,944 thousand representing the largest component. Cash and cash equivalents were $513,657 thousand. Long-term debt declined to $7,590,522 thousand from $8,570,917 thousand at December 31, 2025, while the current portion of long-term debt rose to $996,973 thousand from $380,000 thousand over the same period. Total shareholders' equity was reported at $9,795,271 thousand as of September 30, 2026.

What Was Disclosed

The filing is a Form 10-Q for the quarterly period ended September 30, 2026, covering Royalty Pharma plc's condensed consolidated balance sheets, statements of operations, statements of shareholders' equity, and statements of cash flows, together with accompanying notes and management's discussion and analysis.